UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Date of Report (date of earliest event reported) |
February 14, 2020 |
|
NAVIDEA BIOPHARMACEUTICALS, INC. |
|
(Exact name of registrant as specified in its charter) |
|
Delaware |
001-35076 |
31-1080091 |
|
(State or other jurisdiction |
(Commission |
(IRS Employer |
|
of incorporation) |
File Number) |
Identification No.) |
|
4995 Bradenton Avenue, Suite 240, Dublin, Ohio |
43017 |
|
(Address of principal executive offices) |
(Zip Code) |
|
Registrant's telephone number, including area code |
(614) 793-7500 |
|
|
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
|
Title of Each Class |
|
Trading Symbol(s) |
|
Name of Each Exchange on Which Registered |
|
Common Stock |
|
NAVB |
|
NYSE American |
|
Item 1.01 |
Entry into a Material Definitive Agreement. |
As previously disclosed, on February 14, 2020, Navidea Biopharmaceuticals, Inc. (the “Company” or the “Navidea”) executed an agreement with an investor to purchase 1,647,059 million shares of the Company’s common stock, par value $0.001 per share (the “Shares”), at a price of $0.85 per share, for aggregate gross proceeds to Navidea of approximately $1.4 million.
The Registered Direct Offering is being made pursuant to the Company’s shelf registration statement on Form S‑3 (Registration No. 333-222092), which was declared effective by the Securities and Exchange Commission (the “SEC”) on December 27, 2017, including the prospectus contained therein, as well as a prospectus supplement to be filed with the SEC relating to the offering.
A copy of the opinion of Thompson Hine LLP relating to the legality of the issuance and sale of the Shares is attached as Exhibit 5.1 hereto.
|
Item 3.02 |
Unregistered Sale of Equity Securities. |
The information set forth in Item 1.01 of the Current Report on Form 8-K, filed by the Company on February 14, 2020, is incorporated herein by this reference.
|
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits.
|
Exhibit Number |
Exhibit Description |
|
5.1 |
|
|
23.1 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Navidea Biopharmaceuticals, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
Date: February 18, 2020 |
By: |
/s/ Jed A. Latkin |
|
|
|
|
Jed A. Latkin |
|
|
Chief Executive Officer, Chief Operating Officer, and Chief Financial Officer |
|||